血管生成拟态
三阴性乳腺癌
不对称二甲基精氨酸
一氧化氮
下调和上调
癌症研究
乳腺癌
癌症
医学
生物
转移
内科学
精氨酸
生物化学
氨基酸
基因
作者
Belete Kassa Alemu,Sara Tommasi,Julie-Ann Hulin,Jai Meyers,Arduino A. Mangoni
标识
DOI:10.1016/j.biopha.2025.118013
摘要
Vasculogenic mimicry (VM) is the process by which cancer cells form vascular-like channels to support their growth and dissemination. These channels lack endothelial cells and are instead lined by the tumour cells themselves. VM was first reported in uveal melanomas but has since been associated with other aggressive solid tumours, such as triple-negative breast cancer (TNBC). In TNBC patients, VM is associated with tumour aggressiveness, drug resistance, metastatic burden, and poor prognosis. The lack of effective targeted therapies for TNBC has stimulated research on the mechanisms underpinning VM in order to identify novel druggable targets. In recent years, studies have highlighted the role of nitric oxide (NO), the NO synthesis inhibitor, asymmetric dimethylarginine (ADMA), and dimethylarginine dimethylaminohydrolase 1 (DDAH1), the key enzyme responsible for ADMA metabolism, in regulating VM. Specifically, NO inhibition through downregulation of DDAH1 and consequent accumulation of ADMA appears to be a promising strategy to suppress VM in TNBC. This review discusses the current knowledge regarding the molecular pathways underpinning VM in TNBC, anti-VM therapies under investigation, and the emerging role of NO regulation in VM.
科研通智能强力驱动
Strongly Powered by AbleSci AI